EE91 Clinical Consequences and Associated Costs of Treating Patients With Chronic Lymphocytic Leukemia (CLL) With Bruton Tyrosine Kinase Inhibitors (BTKis) in the First-Line (1L) and Relapsed/Refractory (R/R) Settings. - Crawford, S; Li, H; Srivastava, B; Martin, P; Gahn, J; Rogers, KA (Value in Health, 2024)